Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Increases By 94.9%

Biofrontera Inc. (NASDAQ:BFRI) was the target of a large increase in short interest in May. As of May 31st, there was short interest totalling 15,400 shares, an increase of 94.9% from the May 15th total of 7,900 shares. Based on an average trading volume of 101,600 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.5% of the company’s stock are short sold.

Hedge Funds Weigh In On Biofrontera

An institutional investor recently bought a new position in Biofrontera stock. Rosalind Advisors Inc. acquired a new position in Biofrontera Inc. (NASDAQ:BFRI) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 504,261 shares of the company’s stock, valued at approximately $777,000. Biofrontera comprises 0.7% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th largest position. Rosalind Advisors Inc. owned about 9.91% of Biofrontera at the end of the most recent reporting period. 10.08% of the stock is owned by institutional investors and hedge funds.

Biofrontera Price Performance

Shares of BFRI stock traded up $0.09 during trading hours on Friday, hitting $1.09. 32,709 shares of the company’s stock traded hands, compared to its average volume of 33,581. The stock’s fifty day simple moving average is $1.41 and its two-hundred day simple moving average is $1.74. Biofrontera has a 12-month low of $0.61 and a 12-month high of $13.42.

Biofrontera (NASDAQ:BFRI) last released its earnings results on Wednesday, May 15th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.63) by ($0.22). Biofrontera had a negative net margin of 69.44% and a negative return on equity of 1,390.99%. The business had revenue of $7.91 million for the quarter, compared to analysts’ expectations of $11.52 million. Equities research analysts forecast that Biofrontera will post -3.21 EPS for the current fiscal year.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.